Next Article in Journal
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Next Article in Special Issue
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Previous Article in Journal
Quantification of Bone Fatty Acid Metabolism and Its Regulation by Adipocyte Lipoprotein Lipase
Previous Article in Special Issue
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
Open AccessArticle

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study

1
Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, CIBERONC, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
2
Arquitecto Macide Hospital, SERGAS Group, Av. Residencia s/n, 15405 Ferrol, Spain
3
University Hospital of Ourense, SERGAS Group, Ramon Puga 54, 32005 Ourense, Spain
4
University Hospital of Vigo, SERGAS Group, Pizarro 22, 36204 Vigo, Spain
5
Liquid Biopsy Analysis Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, CIBERONC, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Peter J. K. Kuppen
Int. J. Mol. Sci. 2017, 18(6), 1265; https://doi.org/10.3390/ijms18061265
Received: 10 March 2017 / Revised: 6 June 2017 / Accepted: 7 June 2017 / Published: 13 June 2017
Colorectal cancer (CRC) is one of the major causes of cancer-related deaths. Early detection of tumor relapse is crucial for determining the most appropriate therapeutic management. In clinical practice, computed tomography (CT) is routinely used, but small tumor changes are difficult to visualize, and reliable blood-based prognostic and monitoring biomarkers are urgently needed. The aim of this study was to prospectively validate a gene expression panel (composed of GAPDH, VIL1, CLU, TIMP1, TLN1, LOXL3 and ZEB2) for detecting circulating tumor cells (CTCs) as prognostic and predictive tool in blood samples from 94 metastatic CRC (mCRC) patients. Patients with higher gene panel expression before treatment had a reduced progression-free survival (PFS) and overall-survival (OS) rates compared with patients with low expression (p = 0.003 and p ≤ 0.001, respectively). Patients with increased expression of CTCs markers during treatment presented PFS and OS times of 8.95 and 11.74 months, respectively, compared with 14.41 and 24.7 for patients presenting decreased expression (PFS; p = 0.020; OS; p ≤ 0.001). Patients classified as non-responders by CTCs with treatment, but classified as responders by CT scan, showed significantly shorter survival times (PFS: 8.53 vs. 11.70; OS: 10.37 vs. 24.13; months). In conclusion, our CTCs detection panel demonstrated efficacy for early treatment response assessment in mCRC patients, and with increased reliability compared to CT scan. View Full-Text
Keywords: metastatic colorectal cancer; circulating tumor cells; biomarkers; therapy response metastatic colorectal cancer; circulating tumor cells; biomarkers; therapy response
Show Figures

Graphical abstract

MDPI and ACS Style

Vidal Insua, Y.; De la Cámara, J.; Brozos Vázquez, E.; Fernández, A.; Vázquez Rivera, F.; Villanueva Silva, M.J.; Barbazán, J.; Muinelo-Romay, L.; Candamio Folgar, S.; Abalo, A.; López-López, R.; Abal, M.; Alonso-Alconada, L. Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study. Int. J. Mol. Sci. 2017, 18, 1265.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop